Studies on hemopoietic chimerism following allogeneic bone marrow transplantation in the molecular biology era.
Donor hematopoiesis or donor chimerism in the host following allogeneic bone marrow transplantation (BMT) has appeared crucial to the engraftment process. However, as molecular techniques exploiting neutral variation in human genetic material have been used in the study of chimerism, the detection of residual host cells or mixed hemopoietic chimerism has indicated that donor chimerism is not obligatory following BMT. This review focuses on the detection and significance of mixed chimerism (MC) in patients transplanted for both malignant and non-malignant hemopoietic disease and attempts to tease out the contribution of MC to engraftment, leukemia relapse, graft rejection and long-term disease-free survival.
Socie
G
G
Unite de Biologie des Cellules Souches et Services de greffe de Moelle, Hopital Saint Louis, Paris, France.
Lawler
M
M
Gluckman
E
E
McCann
S R
SR
Brison
O
O
D000741:Anemia, Aplastic / Q000628:therapy; D016026:Bone Marrow Transplantation / Q000473:pathology*; D002678:Chimera; D006086:Graft vs Host Disease; D006410:Hematopoiesis; D006801:Humans; D007938:Leukemia / Q000628:therapy; D018365:Neoplasm, Residual / Q000175:diagnosis; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D017086:beta-Thalassemia / Q000628:therapy